Mumbai, Aug. 18 -- Yesintek was originally approved by the U.S. FDA on 29 November 2024.

The Yesintek single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs.

Yesintek is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients 6 years of age and older, and moderate to severely active Crohn's disease and ulcerative colitis in adults-a range of debilitating autoimmune conditions that affects tens of thousands of Americans.

"This supplemental approval enhances Biocon's comprehensive portfolio of immunology products...